Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven T Staben

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Nature Chemical Biology|December 28, 2022
Targeted degradation via direct 26S proteasome recruitmentCharlene Bashore, Sumit Prakash, Matthew C Johnson, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Bioorganic & Medicinal Chemistry Letters|April 27, 2023
Filling a nick in NIK: Extending the half-life of a NIK inhibitor through structure-based drug designJames J Crawford, Jianwen Feng, Hans D Brightbill, et al.
Cancer Discovery|September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) EfficacyKyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2013
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoformSteven T Staben, Chudi Ndubaku, Nicole Blaquiere, et al.
Journal of Medicinal Chemistry|December 23, 2016
Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)Georgette M Castanedo, Nicole Blaquiere, Maureen Beresini, et al.
Journal of Medicinal Chemistry|October 24, 2022
Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 InhibitorChristopher McBride, Lynnie Trzoss, Davide Povero, et al.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Nature Chemical Biology|December 28, 2022
Targeted degradation via direct 26S proteasome recruitmentCharlene Bashore, Sumit Prakash, Matthew C Johnson, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Bioorganic & Medicinal Chemistry Letters|April 27, 2023
Filling a nick in NIK: Extending the half-life of a NIK inhibitor through structure-based drug designJames J Crawford, Jianwen Feng, Hans D Brightbill, et al.
Cancer Discovery|September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) EfficacyKyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2013
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoformSteven T Staben, Chudi Ndubaku, Nicole Blaquiere, et al.
Journal of Medicinal Chemistry|December 23, 2016
Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)Georgette M Castanedo, Nicole Blaquiere, Maureen Beresini, et al.
Journal of Medicinal Chemistry|October 24, 2022
Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 InhibitorChristopher McBride, Lynnie Trzoss, Davide Povero, et al.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Pageof 5